Citations

Showing 10 of 108104 citations.

Acute Limb Ischemia in Cogan Syndrome
Mohseni, Michael M., Mohseni, Michael , Mohseni, Michael M

Mayo Clinic

American Journal of Case Reports | March 29, 2022 | Volume: 23 | Issue: No issue available | Pages: No page available

10.12659/ajcr.935929 | PMID 35488414 Get It

Declining Colectomy Rates for Nonmalignant Colorectal Polyps in a Large, Ethnically Diverse, Community-Based Population
Alam, Asim , Jiang, Sheng‐Fang, Webb, Kenneth H., Boparai, Eshandeep S., Jue, Terry L., Munroe, Craig A., Gupta, Suraj , Fox, Jeffrey L. , Hamerski, Christopher , Velayos, Fernando, Corley, Douglas A. , Lee, Jeffrey K. , Alam, Asim, Ma, Christopher , Jensen, Christopher D. , Hamerski, Chris M.

Mayo Clinic

Clinical and Translational Gastroenterology | March 28, 2022 | Volume: 13 | Issue: 5 | Pages: e00477

10.14309/ctg.0000000000000477 | PMID 35347095 Get It

INTRODUCTION: Despite studies showing improved safety, efficacy, and cost-effectiveness of endoscopic resection for nonmalignant colorectal polyps, colectomy rates for nonmalignant colorectal polyps have been increasing in the United States and Europe. Given this alarming trend, we aimed to investigate whether colectomy rates for nonmalignant colorectal polyps are increasing or declining in a large, integrated, community-based healthcare system with access to advanced endoscopic resection procedures. METHODS: We identified all individuals aged 50–85 years who underwent a colonoscopy between 2008 and 2018 and were diagnosed with a nonmalignant colorectal polyp(s) at the Kaiser Permanente Northern California integrated healthcare system. Among these individuals, we identified those who underwent a colectomy for nonmalignant colorectal polyps within 12 months after the colonoscopy. We calculated annual colectomy rates for nonmalignant colorectal polyps and stratified rates by age, sex, and race and ethnicity. Changes in rates over time were tested by the Cochran-Armitage test for a linear trend. RESULTS: Among 229,730 patients who were diagnosed with nonmalignant colorectal polyps between 2008 and 2018, 1,611 patients underwent a colectomy. Colectomy rates for nonmalignant colorectal polyps decreased significantly from 125 per 10,000 patients with nonmalignant polyps in 2008 to 12 per 10,000 patients with nonmalignant polyps in 2018 ( P < 0.001 for trend). When stratified by age, sex, and race and ethnicity, colectomy rates for nonmalignant colorectal polyps also significantly declined from 2008 to 2018. DISCUSSION: In a large, ethnically diverse, community-based population in the United States, we found that colectomy rates for nonmalignant colorectal polyps declined significantly over the past decade likely because of the establishment of advanced endoscopy centers, improved care coordination, and an organized colorectal cancer screening program.
Association of hypochloremia with mortality among patients requiring continuous renal replacement therapy
Thongprayoon, Charat , Radhakrishnan, Yeshwanter , Cheungpasitporn, Wisit , Genovez, Jose Zabala, Chewcharat, Api , Zabala Genovez, Jose, Cheungpasitporn, Wisit , Chewcharat, Api , Thongprayoon, Charat , Radhakrishnan, Yeshwanter , Petnak, Tananchai , Genovez, Jose L. Zabala , Qureshi, Fawad , Mao, Michael A. , Kashani, Kianoush

Mayo Clinic

Journal of Nephrology | March 28, 2022 | Volume: 36 | Issue: 1 | Pages: 161-170

10.1007/s40620-022-01305-0 | PMID 35347649 Get It

Abstract Background Serum chloride derangement is common in critically ill patients requiring continuous renal replacement therapy (CRRT). We aimed to assess the association between serum chloride levels before and during CRRT with mortality. Methods This is a retrospective cohort study of critically ill patients receiving CRRT for acute kidney injury from December 2006 through November 2015 in a tertiary referral hospital in the United States. We used logistic regression to assess serum chloride before and mean serum chloride during CRRT as predictors for 90 days mortality after CRRT initiation. The normal reference range for serum chloride was 99–108 mmol/L. Results Of 1282 eligible patients, 25%, 50%, and 25% had hypochloremia, normochloremia, and hyperchloremia, respectively. The adjusted odds ratio for 90 days mortality in patients with hypochloremia before CRRT was 1.82 (95% CI 1.29–2.55). During CRRT, 4%, 70%, 26% of patients had mean serum chloride in the hypochloremia, normochloremia, and hyperchloremia range, respectively. The adjusted odds ratio for 90 days mortality in patients with mean serum chloride during CRRT in the hypochloremia range was 2.96 (95% CI 1.43–6.12). Hyperchloremia before and during CRRT was not associated with mortality. The greater serum chloride range during CRRT was associated with increased mortality (OR 1.29; 95% CI 1.13–1.47 per 5 mmol/L increase). Conclusion Hypochloremia before and during CRRT is associated with higher mortality.
Updating Normal Organ Weights Using a Large Current Sample Database
Bell, Michael D. , Long, Thomas , Roden, Anja C. , Cooper, Felicia , Sanchez, Harold, Trower, Carrie, Hooper, Jody E. , Martinez, Christine, Martinez, Christine

Mayo Clinic

Archives of Pathology & Laboratory Medicine | March 28, 2022 | Volume: 146 | Issue: 12 | Pages: 1486-1495

10.5858/arpa.2021-0287-oa | PMID 35344994 Get It

Context.— Organ weights are an essential part of autopsy analysis. Deviations from normal organ weights provide important clues to disease processes. The assessment of normal organ weights depends on reliable reference tables, but most widely available reference tables are based on data that are either decades old or derived from relatively small sample sizes. Objective.— To provide an updated reference table of organ weights based on contemporary sources and a large sample size. Design.— Organ weights from 4197 carefully screened autopsies performed on adults at the Palm Beach County Medical Examiner's Office in West Palm Beach, Florida, and the Mayo Clinic Hospital in Rochester, Minnesota. Results.— Height and body weight data in this study reflect the well-recognized increases in both variables, but most particularly in body weight, seen during the last decades. The study data show a strong positive association between organ weight and body weight for the heart, liver, and spleen. There is a similar but weaker association between body weight and the weight of the lungs and kidneys. Brain weight is independent of body weight but shows a strong negative association with age. Even when controlling for body weight, men's organs are heavier, except for the weight of the liver, which is comparable in men and women. These associations are in agreement with the findings of previous studies. The current study suggests that, for some of the commonly weighed organs, there has been an increase in median organ weight when compared with existing references. Conclusions.— The tables presented here provide an updated reference that should prove useful to autopsy pathologists in the forensic and hospital settings.
Curvelet Transform-Based Sparsity Promoting Algorithm for Fast Ultrasound Localization Microscopy
You, Qi , Trzasko, Joshua D. , Lowerison, Matthew R. , Chen, Xi , Dong, Zhijie , ChandraSekaran, Nathiya Vaithiyalingam, Llano, Daniel A. , Chen, Shigao , Song, Pengfei , Lowerison, Matthew , Song, Pengfei , ChandraSekaran, Nathiya V.

Mayo Clinic

IEEE Transactions on Medical Imaging | March 28, 2022 | Volume: 41 | Issue: 9 | Pages: 2385-2398

10.1109/tmi.2022.3162839 | PMID 35344488 Get It

Targeted Metagenomic Sequencing-based Approach Applied to 2146 Tissue and Body Fluid Samples in Routine Clinical Practice
Mutchler, Melissa M., Daniels, Matthew L., Wengenack, Nancy L. , Patel, Robin , Flurin, Laure , Wolf, Matthew J, Patel, Robin , Wolf, Matthew J

Mayo Clinic

Clinical Infectious Diseases | March 28, 2022 | Volume: 75 | Issue: 10 | Pages: 1800-1808

10.1093/cid/ciac247 | PMID 35362534 Get It

Abstract Background The yield of next-generation sequencing (NGS) added to a Sanger sequencing–based 16S ribosomal RNA (rRNA) gene polymerase chain reaction (PCR) assay was evaluated in clinical practice for diagnosis of bacterial infection. Methods PCR targeting the V1 to V3 regions of the 16S rRNA gene was performed, with amplified DNA submitted to Sanger sequencing and/or NGS (Illumina MiSeq) or reported as negative, depending on the cycle threshold value. A total of 2146 normally sterile tissues or body fluids were tested between August 2020 and March 2021. Clinical sensitivity was assessed in 579 patients from whom clinical data were available. Results Compared with Sanger sequencing alone (400 positive tests), positivity increased by 87% by adding NGS (347 added positive tests). Clinical sensitivity of the assay that incorporated NGS was 53%, which was higher than culture (42%, P &lt; .001), with an impact on clinical decision-making in 14% of infected cases. Clinical sensitivity in the subgroup that received antibiotics at sampling was 41% for culture and 63% for the sequencing assay (P &lt; .001). Conclusions Adding NGS to Sanger sequencing of the PCR-amplified 16S rRNA gene substantially improved test positivity. In the patient population studied, the assay was more sensitive than culture, especially in patients who had received antibiotic therapy.
Pregnancy outcomes related to the treatment of sarcomas with anthracyclines and/or ifosfamide during pregnancy
Miller, Devon , Livingston, J. Andrew , Park, Yeonhee , Posey, Kristi, Godbole, Sonia, Skubitz, Keith M. , Agulnik, Mark , Davis, Lara E. , Tine, Brian A. Van , Livingston, John A , Skubitz, Keith , Agulnik, Mark , Davis, Lara E , Van Tine, Brian A , Hirbe, Angela C , Parkes, Amanda , Robinson, Steven I. , Hirbe, Angela C.

Mayo Clinic

Cancer Medicine | March 28, 2022 | Volume: 11 | Issue: 18 | Pages: 3471-3478

10.1002/cam4.4707 | PMID 35343652 Get It

AbstractBackgroundSarcomas are rare diagnoses but are seen with relative frequency in adolescents and young adults and thus can present in pregnancy. We sought to study the administration of anthracyclines and/or ifosfamide in pregnancy‐associated sarcomas.Patients and MethodsWe conducted a multi‐institutional retrospective study, identifying sarcoma patients who received anthracyclines and/or ifosfamide during pregnancy. Chart review identified variables related to demographics, cancer diagnosis, therapies, and outcome of the patient and fetus. Wilcoxon rank‐sum test compared two independent samples.ResultsWe identified 13 patients at seven institutions with sarcoma who received anthracyclines and/or ifosfamide during pregnancy, including four bone sarcomas and nine soft tissue sarcomas diagnosed at a mean gestational age of 16.7 ± 5.9 weeks. Only nine patients had live births (9/13, 69.2%), with mean gestational age of 30.8 ± 3.8 weeks at delivery. The four patients with pregnancy loss all received both doxorubicin and ifosfamide, with chemotherapy initiated at 15.5 weeks as compared with 21.3 weeks for those patients with live births (p = 0.016).ConclusionIn this multi‐institutional study of sarcoma chemotherapy regimens administered during pregnancy, we found a high rate of fetal demise that was seen only in patients receiving both doxorubicin and ifosfamide and statistically more likely with chemotherapy initiation earlier in the second trimester. While limited by a small sample size, our study represents the largest study of sarcoma patients that received anthracyclines and/or ifosfamide in pregnancy thus far reported and supports development of an international registry to study concerns raised by our study.
Author response: P2RY14 cAMP signaling regulates Schwann cell precursor self-renewal, proliferation, and nerve tumor initiation in a mouse model of neurofibromatosis
Cram, Jennifer Patritti , Coover, Robert A. , Rizvi, Tilat A. , Chaney, Katherine E. , Ravindran, Ramya , Spinner, Robert J. , Wu, Jianqiang , Cancelas, José A. , Ratner, Nancy

Mayo Clinic

No container title available | March 28, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.7554/elife.73511.sa2 Get It

COVID-19 FAQs in Pediatric Cardiac Surgery: 2022 Perspective and Updates
Levy, Emily R. , Dearani, Joseph A. , Blumenthal, Jennifer , Johnson, Jonathan N. , Overman, David M. , Stephens, Elizabeth H. , Dearani, Joseph A. , Levy, Emily R , Chiotos, Kathleen

Mayo Clinic

World Journal for Pediatric and Congenital Heart Surgery | March 28, 2022 | Volume: 13 | Issue: 3 | Pages: 287-292

10.1177/21501351221085966 | PMID 35341384 Get It

Understanding Suboptimal Response to Immune Checkpoint Inhibitors
Zhu, Mojun , Pedersen, Katrina S. , Foster, Nathan R. , Jaszewski, Brandy L., Liu, Xin , Hirdler, Jacob B. , An, Zesheng , Bekaii‐Saab, Tanios , Yan, Yiyi , Hubbard, Joleen H., Yoon, Harry H. , Revzin, Alexander , Fernández-Zapico, Martín E. , Overman, Michael J. , Dong, Haidong , Bekaii-Saab, Tanios S , Pedersen, Katrina , Zhang, Henan , Hálfdánarson, Þorvarður R. , Boland, Patrick M. , Hubbard, Joleen M. , Wee, Wen , McWilliams, Robert R. , Dong, Haidong

Mayo Clinic

Advanced Biology | March 27, 2022 | Volume: 7 | Issue: 4 | Pages: No page available

10.1002/adbi.202101319 | PMID 35343107 Get It

AbstractImmune checkpoint inhibitors (ICIs), as a novel class of anticancer therapy, can be more efficacious and less toxic than chemotherapy, but their clinical success is confined to certain tumor types. Elucidating their targets, mechanisms and scope of action, and potential synergism with chemotherapy and/or targeted therapies are critical to widen their clinical indications. Treatment response to an ICI targeting programmed death‐1 (anti‐PD‐1) is sought to be understood here by conducting a preplanned correlative analysis of a phase II clinical trial in patients with small bowel adenocarcinoma (SBA). The cytolytic capacity of circulating immune cells in cancer patients using a novel ex vivo cytotoxicity assay is evaluated, and the utility of circulating biomarkers is investigated to predict and monitor the treatment effect of anti‐PD‐1. Baseline expression of Bim and NKG7 and upregulation of CX3CR1 in circulating T cells are associated with the clinical benefit of anti‐PD‐1 in patients with SBA. Overall, these findings suggest that the frequency and cytolytic capacity of circulating, effector immune cells may differentiate clinical response to ICIs, providing a strong rationale to support immune monitoring using patient peripheral blood.